RxDoctor Payments Data

Millicent Edgar

Family · Mitchellville, MDNPI 1437452760

Payments from drug & device makers

$4,803in general payments, 2019–2025

Across 51 payments — averaging $94.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$485
  • Amgen$426
  • Janssen Scientific Affairs, LLC$404
  • AbbVie$352
  • Hologic Sales And Service, LLC$319
  • Coloplast$278
  • plus $3K from 20 others

What the payments were for

  • Food & beverage$4,803100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,803 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$137,358
Medicare patients
218
Services billed
1,288

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$54,740
XifaxanRifaximin13$40,752
EntrestoSacubitril/Valsartan15$11,645
XareltoRivaroxaban11$9,626
FarxigaDapagliflozin Propanediol12$6,591
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$3,973
Clonidine25$2,729
Atorvastatin Calcium189$2,567
Potassium Chloride64$2,316
Carbamazepine ErCarbamazepine13$2,225
Gabapentin72$2,086
Hydroxychloroquine Sulfate11$1,835
Raloxifene Hcl11$1,815
Quetiapine Fumarate108$1,513
Donepezil Hcl52$1,421

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$485$6,59112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.

Other family in Mitchellville

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →